United Statesprotagonist-inc.com
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of peptide-based medicines for hematologic and inflammatory diseases. The company uses a proprietary platform to design constrained peptides that modulate validated biological targets.
Its lead wholly owned program is rusfertide (PTG-300), a hepcidin mimetic in late-stage development for polycythemia vera and other disorders of iron regulation. Protagonist also collaborates with Janssen on oral interleukin-23 receptor antagonists, including JNJ-2113 (formerly PN-235) for immune-mediated conditions. Additional pipeline candidates target gastrointestinal and systemic inflammatory pathways.
Protagonist is headquartered in the United States and conducts research and development across the U.S. and Australia.
None yet. When a new project in the record names Protagonist as owner, partner or investor, it shows here.
Phase 3 data show sustained PASI90/PASI100 and IGA 0/1 responses to Week 112, durable itch improvement, and no new safety signals.
Oral ICOTYDE maintains durable skin clearance through Week 112 and yields high site‑specific clearance rates for scalp, genital, hand/foot and nails.
ICONIC Phase 3: PASI100 rose to 49%/48% (ADVANCE 1/2) by Week52; placebo switchers matched. Adolescents: 57% PASI100, 86% PASI90 at 52w. No new safety signals; fewer AEs vs deucravacitinib.
First targeted oral IL‑23 receptor peptide approved for moderate‑to‑severe plaque psoriasis in adults and ≥12 (≥40kg). Once‑daily pill; ~70% IGA0/1, 55% PASI90 at Week16; safety like placebo.
Rusfertide shows promise in controlling hematocrit and reducing symptoms in polycythemia vera, with FDA review based on positive Phase 3 and long-term study data.
Rusfertide shows promise in controlling hematocrit and reducing phlebotomy in PV patients, meeting key endpoints in Phase 3 VERIFY study.
Rusfertide shows sustained hematocrit control and reduced phlebotomy need in polycythemia vera over 52 weeks, with a consistent safety profile.
